AstraZeneca Results Presentation Deck
AstraZeneca in summary
Pipeline-driven transformation
Global presence
Balanced specialty and
primary-care franchises¹
Leading emerging markets
presence with R&D base
Strong pipeline
22 Phase III medicines and
significant lifecycle projects
Advancing early- and
mid-stage pipeline
Improving financials
Nine blockbuster medicines²
Returned to durable
revenue and earnings growth
Focus on operating
leverage and cash flow
Innovative medicines in Oncology, BioPharmaceuticals³ and rare diseases4
Experienced and proven team
1. In Q1 2021, speciality-care medicines (Oncology, Brilinta, Lokelma, roxadustat and Fasenra) comprised 51% of total revenue 2. Last four quarters 3. Cardiovascular, Renal & Metabolism and Respiratory & Immunology 4. Subject to the Alexion acquisition.
37
4View entire presentation